A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Orally Administered GLPG3970 for 12 Weeks in Adult Subjects With Active Systemic Lupus Erythematosus
Latest Information Update: 22 Oct 2021
At a glance
- Drugs GLPG 3970 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- Acronyms TAPINOMA
- Sponsors Galapagos NV
- 14 Oct 2021 Status changed from recruiting to suspended.
- 11 Jan 2021 New trial record